| Entry |
|
|---|
| Name |
Busulfan (JP17/USP/INN);
Myleran (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C6H14O6S2
|
|---|
| Exact mass |
246.0232
|
|---|
| Mol weight |
246.3018
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Antineoplastic
DG01677 Alkylating agent
DG01721 Methanesulfonate derivative
|
|---|
| Remark |
| Therapeutic category: | 4213 |
|
|---|
| Efficacy |
Antineoplastic, Alkylating agent, Immunosuppressant |
|---|
| Disease |
Chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia [DS: H00004] |
|---|
| Comment |
Busulfan is clearly less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome.
|
|---|
| Target |
DNA |
|---|
| Interaction |
|
|---|
| Structure map |
| map07040 | Antineoplastics - alkylating agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01A ALKYLATING AGENTS
L01AB Alkyl sulfonates
L01AB01 Busulfan
D00248 Busulfan (JP17/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Alkylating Agents
Busulfan
D00248 Busulfan (JP17/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
421 Alkylating agents
4213 Sulfonate esters
D00248 Busulfan (JP17/USP/INN)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00248 Busulfan
Antineoplastics [br08340.html]
D00248
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00248
Pharmacogenomic biomarkers [br08341.html]
Companion diagnostics
D00248
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 14
1 S4a S 16.2149 -21.9100
2 O2a O 17.4273 -22.6100
3 C1b C 18.6397 -21.9100
4 C1b C 19.8522 -22.6100
5 C1b C 21.0646 -21.9100
6 C1b C 22.2770 -22.6100
7 O2a O 23.4895 -21.9100
8 S4a S 24.7019 -22.6100
9 C1a C 15.0024 -21.2100
10 O3c O 16.9209 -20.6867
11 O3c O 15.5214 -23.1115
12 C1a C 25.9144 -23.3100
13 O3c O 25.4243 -21.4059
14 O3c O 23.9838 -23.8069
BOND 13
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 6 7 1
7 7 8 1
8 1 9 1
9 1 10 2
10 1 11 2
11 8 12 1
12 8 13 2
13 8 14 2
|
|---|
